Trabectedin has been approved for second-line treatment of soft tissue sarcomas. However, its efficacy to target sarcoma initiating cells has not been addressed yet. Here, we used pioneer models of myxoid/round cell liposarcoma (MRCLS) and undifferentiated pleomorphic sarcoma (UPS) developed from transformed human mesenchymal stromal/stem cells (MSCs) to evaluate the effect of trabectedin in the cell type responsible for initiating sarcomagenesis and their derived cancer stem cells (CSC) subpopulations.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2ren1SW
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2Gchesc via IFTTT
-
Abstract Determining the cause of unexplained death in all age groups, including infants, is a priority in forensic medicine. The triple r...
-
from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2BeOBVJ via IFTTT
-
This paper presents an adaptive multiuser transceiver scheme for DS-CDMA systems in which pilot symbols are added to users’ data to estimate...
-
from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2rxuJIO via IFTTT
-
Abstract In this paper we present the study of a skull belonging to a young male from the Italian Bronze Age showing three perimortem inju...
-
Find out more about the wide range of A Levels and full time courses available at Longley Park Sixth Form College, the only independent Sixt...
-
Abstract To measure integral doses in image-guided radiation therapy, we developed an integral condenser dosimeter comprising a disposable...
-
Objectives. To assess the association between short-term postoperative cognitive dysfuction (POCD) and inflammtory response in patients unde...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου